Mohammed I, Onyemelukwe G C, Obineche E N, Gupta N, Oyeyinka G O
J Infect. 1984 Sep;9(2):197-202. doi: 10.1016/s0163-4453(84)91468-3.
Meningococcal antibody was measured in 928 persons vaccinated with combined groups A and C polysaccharide antigens in Bauchi State, Nigeria between 1979 and 1982. Protective amounts of antibody were detected by the indirect haemagglutination technique up to 4 years after vaccination. This persistence was observed mainly in adults, although a substantial proportion of older children also had persistent antibody. Titres in younger children fell progressively, and by the third year the mean log2 antibody titre was 1.4; this may not confer protection against disease. A rational policy for vaccination against meningococcal meningitis would be to revaccinate younger children after 2 years, older children after 4 years, and adults after 6-8 or more years.
1979年至1982年间,在尼日利亚包奇州对928名接种A群和C群多糖联合抗原疫苗的人进行了脑膜炎球菌抗体检测。通过间接血凝技术在接种疫苗后长达4年的时间里检测到了具有保护作用的抗体量。这种抗体持久性主要在成年人中观察到,不过相当一部分大龄儿童也有持久性抗体。年幼儿童的抗体滴度逐渐下降,到第三年时,平均log2抗体滴度为1.4;这可能无法提供针对疾病的保护。针对脑膜炎球菌性脑膜炎的合理疫苗接种策略是,2年后对年幼儿童进行再次接种,4年后对大龄儿童进行再次接种,6至8年或更长时间后对成年人进行再次接种。